In Vitro Susceptibility Test of Ciprofloxacin on Different Clinical Isolates

Authors

  • Nwiyi Paul
  • I. J. Ogbonna
  • Osagie Joseph

Abstract

Ciprofloxacin is a quinolone indicated for the treatment of gram positive and gram negative bacterial infections in animals. The study was aimed at evaluating the susceptibility pattern of six different bacteria isolates. The bacteria isolates were Staphylococcus spp., E coli, Pseudomonas spp, Klebsiella spp, Salmonella pullorum and Salmonella gallinarum. The bacteria used for the study were isolated from different animals including chicken. 10% of the total livestock in the farm was used as sample size. The study was skewed towards veterinary science because of the relevance of livestock in the study area. Disc diffusion method was employed and the interpretation of the result was in line with National committee of clinical Laboratory standards. (NCCLS).The rational for using 5 brands of ciprofloxacin was based on the complaint by many farmers on the performance level of some ciprofloxacin at the expense of others. The brands of ciprofloxacin designated as A, B, C, D, and E was obtained from Ariaria International market Aba, Abia State Nigeria. The result of the study showed that brand A and D had 100% effectively, while brand E had 60% affectivity. Staphylococcus spp was 100% susceptible to all the brands of ciprofloxacin followed by E. coli 96.4%, Pseudomanas spp 93.6%. klebsiella spp 90.2%, Salmonella pullorum and Salmonella gallinarum had 88.4% susceptibility for ciprofloxacin. The study showed that there was a significance difference (P<0.05) between brand A compare to all other brands.

References

Nath SK, Foster GA, Mandell LA, Rotstein C et al. 1994. Antimicrobial activity of ciprofloxacin versus cifotaxime: negative effect of serum albumin in binding of ciprofloxacin J. Antimicrobial Chemother 33(6): 1239-1243.

Masood H, Naqvi SB , Aslam N et al 2008. Cost effective analysis of different brands of ciprofloxacin available.

Hwang KP, Tang YF, Shen YH et al. 2009. Activity of ertaperiem, ciprofloxacin, ceftrilaxone, piperacillin – tazobactam and ampicillin – sulbactam against 12 common clinical isolates of community acquired bacteremia .J. Microbiol Immunol Infect 42(5): 433-438

Supp DM, Gardner J, Klingenberg JM, Neely AN et al. 2009. Antibiotic resistance in clinical isolates of Acinetobacter baumanni, pseudomonas aeruginosa and staphylococcus aureus does not impact sensitivity to human beta deferisin.

Liagat I, Sumbal F, Sabri AN et al.2009. Tetracycline and Chloramphenicol efficiency against selected biofilm forming bacteria. Current microbial 59(2): 212-220.

Zarakolu P, Sakizligil B, Unal S et al. 2006. Antimicrobial resistance of Neisseria gonorrhoea strains isolated from sex workers in Ankara. Microbial Bul. 40(2): 69-73

Bell JM, Turnidge JD, Gales AC, Jones RN et al. 2002. Prevalence of external spectrum B-Lactamase (ESBL). Producing clinical isolates in the Asia and South Africa: regional result from Antimicrobial surveillance program (1998-1999). Diagnostic microbial infect disease 42(3):193-198

Khan S, Gupta DK, Khan DN et al.2005. Comparative study of three antimicrobial drugs protocol in cases of intra abdominal sepsis. Kathmandu University Medical J. 3(1): 55-63

Huang TM, Lin TL, Will CC et al.2009. Antimicrobial susceptibility and resistance of chicken Esherichia Coli, Salmonella spp and Pasteurella Mullocida isolates Avian Dis 53(1) 83-93

Khamerich ZR, Afsher AT et al. 2009. Antimicrobial susceptibility, pattern of urinary tract pathogens Saudi: J. Kidney Dis Transpl. 20 (2): 251 – 253

Irfan S, Idrees F, Mehraj V, Habib F, Hasan R et al.2008. Emergence of Carbagenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study, BMC Infect Dis 8:80.

Brusch JL, Garvey T, Corales DO et al.2009, Typhoid fever. Emedicine specialities/infectoious disease/bacterial infections.

Threlfall EJ, Ward LR, Skinner JA, Smith HR, Locky S et al. 1999, Ciprofloxacin resistance Salmonella typhi and treatment failure. Lancet 353(1): 1590 –1591

Capoor MR, Nair D, Hasan AS, Aggarwal P, Gupta B et al. 2006, Typhoid fever: narrowing therapeutic options in India. Southern Asian J. Trop. Med and Public Health 37 (4):1170-4.

Kownhar H, Shankar EM, Rajan R, Rao UA et al. 2007, Emergence of nalidixic acid resistant salmonella enteric serovar. Typhi in India, J Med Microbiol. 2005 (3); 54:999

Saha SK, Darmstadt GL, Baqui AH, Crook DW, Islam MN, Islam M et al.2006. Molecular basis of resistance displayed by highly ciprofloxacin resistant Salmonella enteric serovar Typhi in Bangladesh J. Clin Microbiol. 44 (12):3811-3.

Shoaib MH, Naqvi SH Shiekh D, Hashmi K et al. 2004. Cephalosporin Resistance and B-Lactarnase production in clinical isolates of staphylococcus aureus in Krachi Pak J. Pharm Sci 14 (2): 23-32

Shimizu A, Wakita Y, Ngase S,Okabe T, Hayashi N, Takagi M et al.2001. Antimicrobial susceptibility of Staphylococcus intermedius isolated from healthy and diseased dogs. J.Vet. Med. Sci 63(11):357-360

Faroogi BJ, Shareeq F, Rizvi QK, Qureshi HS , Ashfaq MK et al.2000. Changing pattern of antimicrobial susceptibility of organisms causing community acquired Urinary Tract Infections J. Pak med. Assoc. 50 (11): 369 – 373.

Sen B, Bhattachary M, Niyogi SK et al. 2008. In vitro activity of cefpodoxime an expanded spectrum cephalosporin against Salmonella entrica serotype Typhi. Antimicrob Agents Chemother 52 (2): 802-803.

Downloads

How to Cite

Paul, N., Ogbonna, I. J., & Joseph, O. (2015). In Vitro Susceptibility Test of Ciprofloxacin on Different Clinical Isolates. Asian Journal of Applied Sciences, 3(5). Retrieved from https://ajouronline.com/index.php/AJAS/article/view/3279

Issue

Vol. 3 No. 5 (2015): October 2015

Section

Articles

License

  • Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
  • It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
  • The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
  • The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
  • The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.